Basisstatistiken
| LEI | 5493004HPIB1PBNQ3L69 |
| CIK | 1335105 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lixte Biotechnology Holdings, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| June 4, 2026 |
Exhibit 99.1 Lixte Biotechnology Holdings, Inc. Announces Closing of approximately $16.6 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules BOCA RATON, FLA, June 4, 2026 - Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it intends to close a registered direct offering with accr |
|
| June 4, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 2, 2026, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to th |
|
| June 4, 2026 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-278874 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 2, 2024) LIXTE BIOTECHNOLOGY HOLDINGS, INC. 2,366,503 Shares of Common Stock, Pre-Funded Warrants to Purchase up to 258,859 Shares of Up to 258,859 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 2,366,503 shares of our common stock, par value $0.0001 per |
|
| June 4, 2026 |
REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Exhibit 4.1 REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Warrant Shares: [●] Initial Exercise Date: June [●], 2026 Issuance Date: June [●], 2026 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and |
|
| June 1, 2026 |
Exhibit 99.1 LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE’s Strategic Expansion into AI Energy Infrastructure B |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registr |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) ( |
|
| April 17, 2026 |
STOCK OPTION CANCELLATION AGREEMENT Exhibit 10.2 STOCK OPTION CANCELLATION AGREEMENT THIS STOCK OPTION CANCELLATION AGREEMENT (this “Agreement”) is made and entered into as of , 2026, by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and (“Optionholder”). RECITALS WHEREAS, the Company previously granted to Optionholder the following stock option to purchase shares (the “Shares”) of the Compan |
|
| April 17, 2026 |
RESTRICTED SHARE UNIT AWARD AGREEMENT Exhibit 10.1 RESTRICTED SHARE UNIT AWARD AGREEMENT This Restricted Share Unit Award Agreement (this “Agreement”) is made and entered into as of , 2026 (the “Grant Date”) by and between Lixte Biotechnology Holdings, Inc., a Delaware Corporation (the “Company”), and (the “Grantee”). WHEREAS, the Company has adopted the Lixte Biotechnology, Inc. 2020 Stock Incentive Plan, as amended (the “Plan”) purs |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS |
|
| March 20, 2026 |
AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Amendment”) is dated as of March 18, 2026 (the “Amendment Effective Date”) by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), and Mr. Geordan Pursglove (the “Employee”). The Company and the Employee are a (“Party”) to this Amendment, and one or more of them, as t |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) ( |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (C |
|
| March 10, 2026 |
Exhibit 10.1 AMENDED AND RESTATED SHARE EXCHANGE AGREEMENT among ORBIT CAPITAL INC. LIORA TECHNOLOGIES EUROPE LTD. and LIXTE BIOTECHNOLOGY HOLDINGS, INC. effective as of November 21, 2025 SHARE EXCHANGE AGREEMENT This Amended and Restated Share Exchange Agreement (this “Amended Agreement”), dated as of March 6, 2026, to be effective as of the date of the Original Agreement (as defined below), is e |
|
| February 18, 2026 |
Exhibit 10.1 |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| February 18, 2026 |
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary Exhibit 99.1 LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary BOCA RATON, Fla., February 18, 2026 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the |
|
| February 18, 2026 |
Exhibit 10.2 |
|
| December 31, 2025 |
Exhibit 10.1 SHARE EXCHANGE AGREEMENT among ORBIT CAPITAL INC. and LIXTE BIOTECHNOLOGY HOLDINGS, INC. dated as of December 30, 2025 SHARE EXCHANGE AGREEMENT This Share Exchange Agreement (this “Agreement”), dated as of December 30, 2025, is entered into by and among Orbit Capital Inc., a Cayman Islands corporation (the “Shareholder”), and Lixte Biotechnology Holdings, Inc., a Delaware corporation |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| December 23, 2025 |
Exhibit 10.2 |
|
| December 23, 2025 |
Exhibit 10.1 |
|
| December 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| December 23, 2025 |
Exhibit 99.1 LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial —Plans to double the Number of Patients in Study— —Company Expects Initial Findings to be presented in 2026— BOCA RATON, Fla., December 23, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a biotech company focused on advancing cancer treatments, today announced it is expanding its c |
|
| December 22, 2025 |
Exhibit 10.4 Reference is hereby made to that certain Royalty Agreement dated as of November 24, 2025 (the “Royalty Agreement”), entered into by and between Lixte Biotechnology Holdings, Inc., a Delaware company (the “Company”), and Orbit Capital Inc., a Cayman Islands corporation (the “Royalty Holder”). The Company and the Royalty Holder hereby agree, the Royalty Agreement is hereby deemed null a |
|
| December 22, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], between [] (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to |
|
| December 22, 2025 |
REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Exhibit 4.1 REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Warrant Shares: Initial Exercise Date: [], 2025 Issuance Date: [], 2025 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he |
|
| December 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| December 22, 2025 |
Exhibit 99.1 December 18, 2025 Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a r |
|
| December 22, 2025 |
REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Exhibit 4.2 REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Warrant Shares: Initial Exercise Date: [], 2025 Issuance Date: [], 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| December 22, 2025 |
[Signature Page of [__] Registered Direct Shelf Takedown Placement Agent Agreement Follows] Exhibit 10.2 December [●], 2025 PERSONAL AND CONFIDENTIAL Re: | Registered Direct Shelf Takedown | Placement Agent Agreement Dear Mr. Pursglove: The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Spartan Capital Securities, LLC (“Spartan”) will act as the placement agent on a “best efforts” basis in connection with the proposed Registered |
|
| December 19, 2025 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-278874 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 2, 2024) LIXTE BIOTECHNOLOGY HOLDINGS, INC. 526,342 Shares of Common Stock, Pre-Funded Warrants to Purchase up to 525,000 Shares of Common Stock Common Warrants to Purchase up to 1,051,342 Shares of Common Stock Up to 525,000 Shares of Common Stock Underlying the Pre-Funded Warrant |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) |
|
| November 28, 2025 |
Lixtw-form25 |
|
| November 25, 2025 |
Exhibit 99.1 LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., November 25, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LI |
|
| November 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 25, 2025 (November 21, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdict |
|
| November 25, 2025 |
Exhibit 3.1 LIXTE BIOTECHNOLOGY HOLDINGS, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Lixte Biotechnology Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordanc |
|
| November 25, 2025 |
Exhibit 10.2 ROYALTY AGREEMENT THIS ROYALTY AGREEMENT (this “Royalty Agreement”), dated as of November 24, 2025, is by and between Lixte Biotechnology Holdings, Inc., a Delaware company (the “Company”), and Orbit Capital Inc., a Cayman Islands corporation (the “Royalty Holder”). WHEREAS the Company, the Royalty Holder, and Liora Technologies Europe Ltd., a corporation organized under the laws of E |
|
| November 25, 2025 |
Exhibit 10.1 SHARE EXCHANGE AGREEMENT among ORBIT CAPITAL INC. LIORA TECHNOLOGIES EUROPE LTD. and LIXTE BIOTECHNOLOGY HOLDINGS, INC. dated as of November 21, 2025 SHARE EXCHANGE AGREEMENT This Share Exchange Agreement (this “Agreement”), dated as of November 21, 2025, is entered into by and among Orbit Capital Inc., a Cayman Islands corporation (the “Seller”), Liora Technologies Europe Ltd., a cor |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of reg |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2025 (September 10, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdi |
|
| September 11, 2025 |
Exhibit 99.1 LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions BOCA RATON, Fla., September 10, 2025—LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryptocurrencies to further dive |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2025 (September 1, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdict |
|
| September 4, 2025 |
Exhibit 99.1 LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer — Company Relocates Corporate Headquarters to Boca Raton — Boca Raton, Fla., September 3, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and i |
|
| August 19, 2025 |
Exhibit 99.1 LIXTE Biotechnology Holdings Provides Corporate Update -Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE’s Ongoing Clinical Trials with LB-100- - |
|
| August 19, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| August 14, 2025 |
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency Exhibit 99.1 LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency PASADENA, Calif., August 13, 2025—LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital allocation initiative to acquire cryptocurrency as part of |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| August 7, 2025 |
Agreement for GSK & Lixte Supported Collaborative Study effective as of September 18, 2023.* Exhibit 10.3 Agreement for GSK & LIXTE Supported Collaborative Study Institution: The University of Texas M. D. Anderson Cancer Center Investigator: Amir Jazaeri, MD GSK Investigational Product: Dostarlimab LIXTE Investigational Product: LB-100 Protocol Number and Title: 219582 “Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma (OCCC) using Dostarlimab and LB-100” Effective Dat |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registra |
|
| August 7, 2025 |
August 7, 2025 Robert Weingarten Vice President and Chief Financial Officer LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
|
| July 24, 2025 |
Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 July 24, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attention: Jessica Dickerson Re: Lixte Biotechnology Holdings, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed March 24, 2025 File No. 001-39717 Ladies and Gentlemen: By letter |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2025 (July 18, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of i |
|
| July 16, 2025 |
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements EXHIBIT 99.1 LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements PASADENA, Calif., July 16, 2025—LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel stating that the Company has regained compliance with Nasdaq’ |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2025 (July 15, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of i |
|
| July 16, 2025 |
July 16, 2025 Robert Weingarten Vice President and Chief Financial Officer LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
|
| July 14, 2025 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 July 14, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-1 File No. 333-288120 Ladies and Gentlemen: In accordance with Rule 461 under the Securities |
|
| July 11, 2025 |
Exhibit 99.1 New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 9, 2025—LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical |
|
| July 11, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2025 (July 9, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of in |
|
| July 10, 2025 |
Form of Placement Agent Warrant.* Exhibit 4.10 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 10, 2025 |
As filed with the Securities and Exchange Commission on July 10, 2025 As filed with the Securities and Exchange Commission on July 10, 2025 Registration No. |
|
| July 10, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| July 8, 2025 |
Exhibit 4.1 REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Warrant Shares: [●] Initial Exercise Date: July 3, 2025 Issuance Date: July 7, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the |
|
| July 8, 2025 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-278874 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 2, 2024) LIXTE BIOTECHNOLOGY HOLDINGS, INC. 210,675 Shares of Common Stock Pre-Funded Warrants to Purchase up to 763,351 Shares of Common Stock We are offering (i) 210,675 shares of our common stock, par value $0.0001 per share (“Common Stock”), at a price of $1.54 per share and (i |
|
| July 8, 2025 |
Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering Exhibit 99.1 Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering PASADENA, CALIF, July 8, 2025 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale of approximately $ |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2025 (July 3, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of inc |
|
| July 8, 2025 |
Form of Placement Agent Agreement Exhibit 10.2 July 3, 2025 PERSONAL AND CONFIDENTIAL Mr. Geordan Pursglove, Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 Re: LIXT | RD | Placement Agent Agreement Dear Mr. Pursglove: The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Spartan Capital Securities, LLC (“Sp |
|
| July 8, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 3, 2025, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t |
|
| July 3, 2025 |
Form of Placement Agent Agreement EXHIBIT 10.2 June 30, 2025 PERSONAL AND CONFIDENTIAL Mr. Geordan Pursglove, Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 Re: LIXT | PIPE | Placement Agent Agreement Dear Mr. Pursglove: The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Spartan Capital Securities, LLC ( |
|
| July 3, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 3, 2025 |
Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market EXHIBIT 99.1 Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market PASADENA, CALIF, July 1, 2025 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive agreement with accredited investors on the purchase and |
|
| July 3, 2025 |
EXHIBIT 4.1 CERTIFICATE OF DESIGNATIONS SERIES B CONVERTIBLE PREFERRED STOCK OF LIXTE BIOTECHNOLOGY HOLDINGS, INC. (pursuant to Section 151 of the Delaware General Corporation Law) Lixte Biotechnology Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that the Board of Directors of the Corporation (the “Board of Direct |
|
| July 3, 2025 |
EXHIBIT 99.2 Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market PASADENA, CALIF, July 2, 2025 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purchase and sale of approximatel |
|
| July 3, 2025 |
Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2025, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to |
|
| July 3, 2025 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2,2025 (June 30, 2025) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of inc |
|
| June 26, 2025 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 June 26, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-1 File No. 333-288120 Ladies and Gentlemen: Reference is made to our letter, filed as corresp |
|
| June 24, 2025 |
As filed with the Securities and Exchange Commission on June 23, 2025 As filed with the Securities and Exchange Commission on June 23, 2025 Registration No. |
|
| June 24, 2025 |
Form of Placement Agent Agreement* Exhibit 1.1 June [●], 2025 PERSONAL AND CONFIDENTIAL Mr. Geordan Pursglove, Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 Re: LIXT | Best Efforts Secondary Offering | Placement Agent Agreement Dear Mr. Pursglove: The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Sparta |
|
| June 24, 2025 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 June 24, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-1 File No. 333-288120 Ladies and Gentlemen: In accordance with Rule 461 under the Securities |
|
| June 24, 2025 |
June 24, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 18, 2025 |
Form of Registered Pre-Funded Warrant to Purchase Common Stock* Exhibit 10.26 REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2025 Issuance Date: [●], 2025 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the cond |
|
| June 18, 2025 |
Consent of Director Nominee – Peter Stazzone* Exhibit 99.1 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Lixte Biotechnology Holdings, Inc. (the “Company”) of the Registration Statement on Form S-1, and in all subsequent amendments and post-effective amendments or supplements thereto, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Ru |
|
| June 18, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| June 18, 2025 |
Form of Underwriting Agreement* Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2025 Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 Ladies and Gentlemen: Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Spartan Capital Securities, LLC (the “Underwriter”) an aggregate of [●] shares |
|
| June 18, 2025 |
Exhibit 10.27 Lixte Biotechnology Holdings, Inc. - Lock-up Agreement [●], 2025 Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 Ladies and Gentlemen: The undersigned understands that Spartan Capital Securities, LLC (the “Underwriter”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Lixte Biotechnology Holdings, Inc., a Delaware corpora |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 17, 2025 As filed with the Securities and Exchange Commission on June 17, 2025 Registration No. |
|
| June 18, 2025 |
Form of Placement Agent Warrant to Purchase Common Stock** Exhibit 10.28 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) CALENDAR DAYS FOLLOWING [●], 202 |
|
| June 17, 2025 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) to the Employment Agreement is made as of June 16, 2025 (the “Amendment Date”) between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and Bastiaan van der Baan (“Employee”), with reference to the following: A. The Company and Employee entered into a three-year Employment Agreement dated as |
|
| June 17, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), with an address of 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101, and Geordan Pursglove, an individual (the “Employee”), with an address of 222 Yamato Road, Suite 260, Boca Raton, Florida 33431, and shall be |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (C |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registr |
|
| May 7, 2025 |
May 7, 2025 Bastiaan van der Baan President and Chief Executive Officer Lixte Biotechnology Holdings, Inc. |
|
| May 2, 2025 |
As Confidentially Submitted to the Securities and Exchange Commission on , 2025 This draft Registration Statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains strictly confidential. |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| April 11, 2025 |
Filed pursuant to Rule 424(b)(4) Registration No. 333-286385 PROSPECTUS 467,393 Shares of Common Stock 434,784 Shares of Common Stock Issuable Upon the Exercise of Outstanding 2025 Warrants 32,609 Shares of Common Stock Issuable Upon the Exercise of 2025 Placement Agent Warrants LIXTE BIOTECHNOLOGY HOLDINGS, INC. Common Stock Pursuant to this prospectus, the selling stockholders identified herein |
|
| April 9, 2025 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 April 9, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-1 File No. 333-286385 Ladies and Gentlemen: In accordance with Rule 461 under the Securities |
|
| April 9, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| April 9, 2025 |
As filed with the Securities and Exchange Commission on April 9, 2025. As filed with the Securities and Exchange Commission on April 9, 2025. Registration No. 333-286385 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2903526 (State or other jurisdiction o |
|
| April 8, 2025 |
April 8, 2025 Bastiaan van der Baan Chief Executive Officer Lixte Biotechnology Holdings, Inc. |
|
| April 4, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025. As filed with the Securities and Exchange Commission on April 4, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 100 20-2903526 (State or other jurisdiction of incorporation or organiz |
|
| March 31, 2025 |
Exhibit 99.1 LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025—LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LI |
|
| March 31, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| March 27, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| March 27, 2025 |
Exhibit 99.1 LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer -Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100’s Potential in Enhancing Cancer Immunotherapies |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS |
|
| March 14, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| March 14, 2025 |
Exhibit 10.1 |
|
| March 11, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| March 11, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 11, 2025 |
Exhibit 99.1 New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form — As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 — PASADENA, CALIF., March 10, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company, today an |
|
| February 25, 2025 |
Exhibit 99.1 LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer - Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab - PASADENA, CALIF., February 25, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a c |
|
| February 25, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| February 21, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| February 18, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| February 13, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 13, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 13, 2025 |
Exhibit 99.2 LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PASADENA, CALIF., Feb. 13, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced the closing of its previously announced registered direct offering priced at-the-marke |
|
| February 13, 2025 |
Exhibit 99.1 LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PASADENA, CALIF., Feb. 11, 2025 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,7 |
|
| February 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 11, 2025, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| February 12, 2025 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 434,784 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-278874 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 2, 2024) LIXTE BIOTECHNOLOGY HOLDINGS, INC. 434,784 Shares of Common Stock We are offering 434,784 shares of our common stock, par value $0.0001 per share (“Common Stock”), at a price of $2.415 per share, pursuant to this prospectus supplement, the accompanying prospectus, and a se |
|
| February 10, 2025 |
Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 February 10, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: LIXTE BIOTECHNOLOGY HOLDINGS,INC - Request to Withdraw Registration Statement on Form S-1 - File No. 333-282781 Ladies and Gentlemen: Pursuant to Rule 477 under the Sec |
|
| January 10, 2025 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Up to $1,700,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-278874 PROSPECTUS SUPPLEMENT (To Prospectus dated April 23, 2024) LIXTE BIOTECHNOLOGY HOLDINGS, INC. Up to $1,700,000 Common Stock We have entered into an At-the-Market Sales Agreement, or the Sales Agreement, with WallachBeth Capital, LLC, or the Sales Agent or WallachBeth, acting as our sales agent, dated as of January 6, 2025, relating to th |
|
| January 6, 2025 |
Exhibit 10.1 LIXTE Biotechnology Holdings, Inc. Common Stock (par value $0.0001 per share) At-The-Market Issuance Sales Agreement January 6, 2025 WallachBeth Capital LLC 185 Hudson St Jersey City, NJ 07302 Ladies and Gentlemen: LIXTE Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WallachBeth Capital LLC (the “Agent”), as follows |
|
| January 6, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| December 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| December 2, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| December 2, 2024 |
Amendment 3 to Development Collaboration Agreement Exhibit 10.1 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of reg |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 5, 2024 |
As filed with the Securities and Exchange Commission on November 5, 2024. As filed with the Securities and Exchange Commission on November 5, 2024. Registration No. 333-282781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 100 20-2903526 (State or other jurisdiction |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 1, 2024 |
Form of Common Stock Purchase Warrant* Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 1, 2024 |
Form of Placement Agent Warrant* Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 1, 2024 |
Form of Placement Agency Agreement* Exhibit 10.23 Placement Agency Agreement [], 2024 Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 Attn: Chief Executive Officer Dear Mr. Bastiaan van der Baan: This letter (the “Agreement”) constitutes the agreement between WallachBeth Capital LLC (the “Placement Agent”) and Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), tha |
|
| November 1, 2024 |
Exhibit 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINDS, INC. Warrant Shares: [] Issue Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| November 1, 2024 |
As filed with the Securities and Exchange Commission on November 1, 2024. As filed with the Securities and Exchange Commission on November 1, 2024. Registration No. 333-282781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 100 20-2903526 (State or other jurisdiction |
|
| November 1, 2024 |
Form of Securities Purchase Agreement* Exhibit 10.24 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [], 2024, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHE |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| October 23, 2024 |
As filed with the Securities and Exchange Commission on October 22, 2024. As filed with the Securities and Exchange Commission on October 22, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 100 20-2903526 (State or other jurisdiction of incorporation or orga |
|
| September 5, 2024 |
Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies Exhibit 99.1 LIXTE Receives U.S. Patent Issue Notification for Immune Oncology Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., September 4, 2024 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPT |
|
| September 5, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| August 26, 2024 |
Exhibit 99.1 First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company PASADENA, Calif. August 26, 2024 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer |
|
| August 26, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| August 23, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| August 19, 2024 |
Exhibit 99.2 LIXTE Biotechnology Provides Update On Recent Activities and Developments -Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXT |
|
| August 19, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| August 19, 2024 |
Exhibit 99.1 LIXTE Biotechnology Holdings to Present at Two Investor Conferences -Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., August 15, 2024 - LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical co |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registra |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| June 14, 2024 |
Exhibit 99.1 LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) - LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinic |
|
| June 14, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (C |
|
| June 14, 2024 |
Exhibit 10.1 Clinical Trial Agreement Clinical Trial: Phase Ib Study With The Combination Of LB–100 (PP2A Inhibitor) And Atezolizumab (PD–L1 Inhibitor) In Metastatic Colorectal Cancer Patients – The CoLBAt Trial Protocol: CTIS number 2023-505534-98 Investigational Product: LB–100 Effective date of agreement: date of last Party’s signature on this Agreement The undersigned, A. Stichting Het Nederla |
|
| June 14, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (C |
|
| June 5, 2024 |
Exhibit 10.1 CONSULTING AGREEMENT This CONSULTING Agreement (the “Agreement”) is entered into as of May 31, 2024 and is effective as of July 1, 2024 (the “Effective Date”), and is by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation, having its principal place of business located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101 (the “Company”), and Jan H.M |
|
| June 5, 2024 |
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer Exhibit 99.1 LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer PASADENA, Calif., June 3, 2024 — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Sche |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| May 20, 2024 |
LIXTE Biotechnology Holdings Provides Update on Recent Activities EXHIBIT 99.1 LIXTE Biotechnology Holdings Provides Update on Recent Activities ▪ Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality” ▪ Presentation at MedInvest Biotech and Pharma Investor Conference ▪ Co-Sponsorship/Presentation of Workshop at Harvard University’s Dana Farber Cancer Institute PASADENA |
|
| May 20, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registr |
|
| May 9, 2024 |
Exhibit 99.1 LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston PASADENA, CA, May 8, 2024 (GLOBE NEWSWIRE) - LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasd |
|
| May 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| May 3, 2024 |
Dated May 3, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. Common Stock Preferred Stock Debt Securities Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-278874 Dated May 3, 2024 PROSPECTUS LIXTE BIOTECHNOLOGY HOLDINGS, INC. $50,000,000 Common Stock Preferred Stock Debt Securities Warrants Rights Units From time to time, we may offer and sell up to an aggregate amount of $50,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also |
|
| May 3, 2024 |
583,334 Shares of Common Stock LIXTE BIOTECHNOLOGY HOLDINGS, INC. Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-278874 Prospectus 583,334 Shares of Common Stock LIXTE BIOTECHNOLOGY HOLDINGS, INC. Common Stock Pursuant to this prospectus, the selling stockholder identified herein is offering on a resale basis 583,334 shares of our common stock, par value $0.0001 per share, issuable upon exercise of certain common stock warrants (the “Warrants”). |
|
| April 30, 2024 |
As filed with the Securities and Exchange Commission on April 30, 2024 As filed with the Securities and Exchange Commission on April 30, 2024 Registration No. |
|
| April 30, 2024 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 April 30, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-3 Filed April 23, 2024 File No. 333-278874 Ladies and Gentlemen: In accordance with Rule 461 |
|
| April 29, 2024 |
United States securities and exchange commission logo April 29, 2024 Bas van der Baan Chief Executive Officer Lixte Biotechnology Holdings, Inc. |
|
| April 23, 2024 |
eXHIBIT 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| April 23, 2024 |
As filed with the Securities and Exchange Commission on April 23, 2024 As filed with the Securities and Exchange Commission on April 23, 2024 Registration No. |
|
| April 23, 2024 |
Exhibit 4.7 LIXTE BIOTECHNOLOGY HOLDINGS, INC. INDENTURE Dated as of , 20 Trustee TABLE OF CONTENTS (cont.) Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II THE SECURITIES 4 Section 2.1 Issuable in Series 4 Section 2.2 E |
|
| March 28, 2024 |
Exhibit 99.1 NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA – (March 27, 2024) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Compan |
|
| March 28, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| March 22, 2024 |
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- Exhibit 99.1 LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments - Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers - PASADENA, Calif., March 21, 2024 – LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company develo |
|
| March 22, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| March 19, 2024 |
Exhibit 10.16 LIXTE BIOTECHNOLOGY HOLDINGS, INC. COMPENSATION CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) believes that it is in the best interests of Lixte Biotechnology Holdings, Inc. (the “Company”) and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation ph |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS |
|
| February 27, 2024 |
EXHIBIT 99.1 Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research Conference In Dublin, Ireland on February 27 - 29, 2024 Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, February 27, 2024 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Com |
|
| February 27, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| February 26, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| February 26, 2024 |
Exhibit 99.1 LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, February 26, 2024 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement wi |
|
| February 26, 2024 |
Exhibit 10.1 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), whi |
|
| January 30, 2024 |
EXHIBIT 99.1 First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial PASADENA, CA, January 29, 2024 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death re |
|
| January 30, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 27, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| November 28, 2023 |
Exhibit 10.1 LIXTE BIOTECHNOLOGY HOLDINGS, INC. 2020 STOCK INCENTIVE PLAN (as amended) 1. Purpose. The purpose of the Plan is to assist the Company in attracting, retaining, motivating, and rewarding certain employees, officers, directors, and consultants of the Company and its Affiliates and promoting the creation of long-term value for stockholders of the Company by closely aligning the interest |
|
| November 13, 2023 |
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations Exhibit 99.1 LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations PASADENA, Calif., November 13, 2023 – LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress. C |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| November 9, 2023 |
Exhibit 10.3 |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of reg |
|
| November 9, 2023 |
Exhibit 10.5 |
|
| October 17, 2023 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 13, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification |
|
| October 17, 2023 |
Exhibit 99.1 LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer PASADENA, CA, October 16, 2023 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute |
|
| October 17, 2023 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT 2 TO DEVELOPMENT COLLABORATION AGREEMENT THIS AMENDMENT IS MADE ON October 3, 2023 AND ENTERED INTO BY AND BETWEEN: 1. LIXTE BIOTECHNOLOGY HOLDINGS, INC. (“Lixte”), with its office and place of business at 680 E |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 27, 2023 |
EXHIBIT 99.1 LIXTE Appoints Bas van der Baan as President and Chief Executive Officer Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, September 26, 2023 - LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of |
|
| September 27, 2023 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into and effective as of September 26, 2023 (the “Effective Date”) by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation having its principal place of business located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101 (the “Company”), and Bastiaan van der Baan (the “Empl |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporatio |
|
| September 20, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporatio |
|
| September 20, 2023 |
EXHIBIT 99.1 LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASA |
|
| August 18, 2023 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 August 18, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273932 Ladies and Gentlemen: In accordance with Rule 4 |
|
| August 15, 2023 |
United States securities and exchange commission logo August 15, 2023 John Kovach Chief Executive Officer Lixte Biotechnology Holdings, Inc. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lixte Biotechnology Holdings, Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registra |
|
| July 21, 2023 |
Exhibit 99.1 LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced registered direct offering of 583,334 share |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No. |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| July 20, 2023 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC. Warrant Shares: Initial Exercise Date: July 20, 2023 Issue Date: July 20, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| July 20, 2023 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 20, 2023 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-252430 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 5, 2021) LIXTE BIOTECHNOLOGY HOLDINGS, INC. 180,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 403,334 Shares of Common Stock Up to 403,334 Shares of Common Stock underlying such Pre-Funded Warrants We are offering (i) 180,000 shares of our common stock, par |
|
| July 20, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 20, 2023 |
Exhibit 99.1 LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has entered into a securities purchase agreement with a single health-care focus |
|
| July 20, 2023 |
Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July [18], 2023, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (C |
|
| June 26, 2023 |
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements PASADENA, CA, June 23, 2023 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| June 6, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF LIXTE BIOTECHNOLOGY HOLDINGS, INC. (a Delaware corporation) Pursuant to Section 242 of the Delaware General Corporation Law, the undersigned, being the Chief Executive Officer of Lixte Biotechnology Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Co |
|
| May 10, 2023 |
Exhibit 10.1 |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registr |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| May 10, 2023 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252430 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated September 20, 2021) LIXTE BIOTECHNOLOGY HOLDINGS, INC. Common Stock This prospectus supplement amends, supplements and supersedes our prospectus supplement, dated September 20, 2021 (the “September 2021 Prospectus”), related to an At-the-Market Sales Agreement with WestPark Capital, I |
|
| April 25, 2023 |
Exhibit 99.1 LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE’s Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in m |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) ( |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 5, 2023 |
EXHIBIT 99.1 LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does |
|
| April 5, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation) (C |
|
| March 29, 2023 |
Exhibit 10.21 LIXTE BIOTECHNOLOGY HOLDINGS, INC. Insider Trading Policy This Insider Trading Policy provides the standards of Lixte Biotechnology Holdings, Inc. (the “Company”) on trading and causing the trading of the Company’s securities or securities of other publicly-traded companies while in possession of confidential information. This Policy is divided into two parts: Part I prohibits tradin |
|
| March 29, 2023 |
Exhibit 10.15 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (the “Amendment”) to Employment Agreement is made as of November 6, 2022 (the “Amendment Date”) between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and Eric Forman (“Employee”) with reference to the following: 1) The parties hereto have entered into an Employment Agreement dated July 15, 20 |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS |
|
| March 29, 2023 |
Exhibit 21.1 Lixte Biotechnology Holdings, Inc. Subsidiaries as of December 31, 2022 Subsidiary Name Jurisdiction of Incorporation Percentage Owned Lixte Biotechnology, Inc. Delaware 100% |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) delaware 001-39717 20-2903526 (State or other jurisdiction of incorporation |
|
| February 15, 2023 |
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH Exhibit 99.1 LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM PASADENA, CA – (February 14, 2023) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nas |
